But in 2004, a groundbreaking new treatment called anti-VEGF—including drugs such as Lucentis, Eylea, and Avastin—became available. These drugs work to stop the blood vessels from growing ...

Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR ...

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.

but that was offset by higher rates of inflammatory reactions in the eyes – some of which could be sight threatening – compared to rival anti-VEGF therapy Eylea (aflibercept) from Bayer and ...

NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Introduction/Background Anti-VEGF Dosing Regiments: Review of the Pertinent Studies Comparing the Anti-VEGF Dosing Strategies Conclusions References While ...

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...

Regeneron offered a price concession that lowered Eylea’s selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications ...